Tango Therapeutics
Mu-Sen Liu is a Senior Scientist I in Biochemistry at Tango Therapeutics since April 2022, previously serving as a Scientist I in Lead Discovery (Structural Biology) at Rheos Medicines from February 2021 to March 2022. Liu has extensive experience in protein production, enzymatic screening, and structural analysis, particularly utilizing X-ray crystallography for target structure determination. Prior roles include Postdoctoral Research Fellow at The University of Texas at Austin, focusing on the kinetics of CRISPR/Cas9, and various positions in academia and industry, including internships and military service. Liu holds a Ph.D. in Biochemistry from National Taiwan University, complemented by a Master's degree in Biochemistry and Molecular Biology and a Bachelor's degree in Biomedical Sciences.
Tango Therapeutics
3 followers
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients.